2026-06-08T08:27:54Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/1018562025-08-29T16:58:51Zcom_20.500.14352_14col_20.500.14352_15

00925njm 22002777a 4500 dc Martínez De La Casa Fernández-Borrella, José María author Marcos Parra, María Teresa author Millá Griñó, Elena author Laborda, Teresa author Giménez Gomez, Rafael author Larrosa, José Manuel author Urcola, Aritz author Teus, Miguel Ángel author Perucho Martínez, Susana author 2024 This paper evaluates the effectiveness and safety of XEN63 stent, either standalone or in combination with phacoemulsification, in patients with primary open-angle glaucoma (POAG). Eighty eyes from 80 patients with medically uncontrolled POAG were assigned to undergo XEN63 implant. The primary outcome was the surgical success, defined as an intraocular pressure (IOP) lowering from preoperative values ≥ 20% and an IOP absolute value between 6 and 18 mmHg, with or without antiglaucoma medications. Forty-three (53.7%) eyes underwent XEN63-standalone and 37(46.2%) eyes a XEN63 + Phacoemulsification procedure. Success rate was 68.8% (55/80) eyes in the overall study sample, 69.8% (30/43) eyes in the XEN63-standalone group; and 67.6% (25/37) eyes in the XEN63 + Phaco group (p = 0.6133). Preoperative IOP was significantly lowered from 22.1 ± 4.9 mmHg and 19.8 ± 3.7 mmHg to 14.7 ± 5.3 mmHg and 13.8 ± 3.4 mmHg in the XEN63-standalone and XEN63 + Phaco groups, respectively (p < 0.0001 each, respectively); without significant differences between them at any of the time-points measured. Preoperative number of ocular-hypotensive drugs was significantly reduced from 2.3 ± 0.8 to 0.3 ± 0.7 drugs, from 2.5 ± 0.7 to 0.3 ± 0.7 drugs; and from 2.0 ± 0.8 to 0.3 ± 0.7 drugs, in the overall, XEN63-standalone, and XEN63 + Phaco groups, respectively. Regarding safety, 3(42.5%) eyes had transient hypotony at some point during the study, although only in one (1.2%) eye was clinically significant. Four (5.0%) eyes underwent a needling, 4 (5.0%) eyes underwent surgical-bleb-revision, 1 (1.2%) eye required a device replacement and 1 (1.2%) eye a device removal due to maculopathy. XEN63, either alone or in combination with phacoemulsification, significantly lowered IOP and reduced the number of ocular hypotensive medications. The rate of ocular hypotony was relatively high, although it was clinically relevant only in one eye. Martínez-de-la-Casa JM, Marcos-Parra MT, Millá-Griñó E, Laborda T, Giménez-Gomez R, Larrosa JM, Urcola A, Teus MÁ, Perucho-Martínez S. Effectiveness and safety of XEN63 in patients with primary-open-angle glaucoma. Sci Rep. 2024 Feb 24;14(1):4561. doi: 10.1038/s41598-024-55287-z. PMID: 38402310; PMCID: PMC10894194. 2045-2322 10.1038/s41598-024-55287-z https://hdl.handle.net/20.500.14352/101856 https://doi.org/10.1038/s41598-024-55287-z 38402310 https://www.nature.com/articles/s41598-024-55287-z Effectiveness and safety of XEN63 in patients with primary-open-angle glaucoma